Cassava Sciences' stock is highly shorted, with potential reward tied to the upcoming Phase 3 trial results for simufilam.

In Sunday’s Week 9 win over the Jacksonville Jaguars, Philadelphia Eagles star Saquon Barkley pulled off one of the more ...

Cassava Sciences' RETHINK-ALZ trial is nearing data release. See why SAVA stock could see volatility depending on trial ...

Hidden in political commercials and campaign announcements, not seen through the issues of inflation, illegal immigration, drug infiltration and the like, are 7 million Americans affected by Alzheimer ...

If you find yourself sleepy during your daily activities in your older age, you may need to consider it more than an inconvenience — since the fatigue may indicate you're at higher risk for developing ...

The Journal of the Alzheimer’s Association” — has linked the active ingredient in both of these drugs, semaglutide, to ...

Semaglutide is associated with a reduced risk for a first-time Alzheimer disease (AD) diagnosis compared with other antidiabetic medications.

In people with mild cognitive impairment, galantamine, compared to placebo, may make little to no difference in improving memory or the ability to do self-care activities. However, participants who ...

Dr Lotte Knudson, a scientist from Copenhagen, revolutionized research into drugs used by millions to lose weight. She has ...

Alzheimer’s disease patients prescribed fistfuls of daily drugs are at greater risk of harm, a new study warns.Patients ...

Peter joined Alzheimer’s Research UK in 2014 and has overseen the significant growth of our work with individual philanthropists, trusts and foundations. He leads on our fundraising for our strategic ...

In a small early trial using a transcranial magnetic stimulation procedure, scientists were able to target a key brain ...